FDA Oncologic Drugs Advisory Committee Votes in Favor of Cilta-Cel as Early Treatment for Multiple Myeloma

The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.

Related Keywords

United States ,Irene Ghobrial ,Helkha Peredo Pinto ,Ravi Madan ,Susan Lattimore ,Mary Kwok ,University Of Washington School Medicine ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,Janssen Biotech Inc ,Dana Farber Cancer Institute ,Oncologic Drugs Advisory Committee ,Harvard Medical School ,Biologics Licensing Application ,Janssen Biotech ,Janssen Pharmaceutical Companies ,Washington School ,